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Psoriasis, a chronic inflammatory skin disease, is not yet curable, and its precise causes remain 
unclear. Nevertheless, several lines of evidence support that psoriasis is a multifactorial disease. 
Because psoriasis occurs in connection with stress and mood disorders, the genes in serotonergic 
system may be involved in psoriasis with regard to etiology and pathogenesis. Such molecular impacts 
supported by scientific evidence on serotonergic gene expression changes and genetic polymorphisms 
have been increasingly highlighted. The serotonergic system has also received considerable attention 
as a potential target for the therapy of psoriasis. Here, we summarize the current knowledge about role 
of genes in serotonergic system in psoriasis and point out possible directions of future studies.  
 





Psoriasis is a chronic inflammatory skin disease affecting 
about 3% of the population worldwide (Schon and 
Boehncke, 2005; Lowes et al., 2007). It is thought to be a 
multigenic disease, the expression of which is dependent 
on certain external triggering factors (Henseler, 1998). It 
is also an autoimmune disease in which the role of T cells 
in pathogenesis has primarily been highlighted (Uyemura 
et al., 1993; Prinz, 2003; Bos et al., 2005). Consistently, 
lymphocyte subsets in peripheral blood of psoriatic 
patients have been found to be varied depending on 
disease severity (Langewouters et al., 2008; van Lingen 
et al., 2008). To support the immune hypothesis, novel 
immune regulatory molecules have been identified in 
peripheral blood mononuclear cells from psoriatic patients 
when analyzed using gene expression profiling (Kunz et 
al., 2004; Koczan et al., 2005). In the omics era, such 
omics techniques as functional genomics and proteomics 
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possibly responsible for mechanisms underlying patho-
genesis of psoriasis (Trcka and Kunz, 2006). For instance, 
certain immune molecules have been discovered in 
serum samples of psoriatic patients using the proteomics 
technique (Liu et al., 2007). It is noteworthy that these 
particular data are intriguing although they are preli-
minary. Still, more studies with respect to preclinical and 
clinical settings should be carried out to verify the pre-
existing data.  
Oxidative stress in keratinocytes is considered a factor 
in an aetiopathogenic concept which considers psoriasis 
as a typical inflammatory process described by increased 
antioxidant activity and overexpression of apoptotic 
receptors (Dimon-Gadal et al., 2000; Shilov and Sergienko, 
2000). Oxidative stress is subsequently emphasized and 
evidently proved to associate with pathogenesis of 
psoriasis (Relhan et al., 2002; Trouba et al., 2002; Rocha-
Pereira et al., 2004; Okayama, 2005; Sezer et al., 2007; 
Toker et al., 2009; Zhou et al., 2009). For this reason, 
antioxidant strategies have proven to be beneficial thera-
peutics. For example, pharmacological behavior of avarol-
3'-thiosalicylate, a promising antipsoriatic agent, has 
been experimentally demonstrated to possess antioxidant 
properties, thus suppressing the inflammatory process 
(Amigo et al., 2007). Since diet has also been suggested 
to play a role in the aetiology and pathogenesis of 
psoriasis, various dietary factors showing such beneficial 
effects as anti-inflammatory and antioxidant properties 





Kharaeva et al., 2009). It has been well docu-mented that 
a number of patients with psoriasis show an elevated 
sensitivity to gluten, a food allergen. Thus, treatment using 
gluten-free diet is considered one of the alternative thera-
peutic approaches for patients with psoriasis (Wolters, 
2005).  
Psoriasis can also be provoked or exacerbated by a 
variety of diverse environmental factors, particularly infec-
tions and drugs. Several lines of evidence have been 
linked to altered immune responses associating with 
psoriasis, especially in predisposed individuals. These 
include bacteria (Streptococcus pyogenes, Staphylococcus 
aureus), fungi (Malassezia, Candida albicans), and 
viruses (papillomaviruses, retroviruses, endogenous 
retroviruses) although precise mechanisms caused by 
some of these microorganisms remain to be elucidated 
(Fry and Baker, 2007; Prinz, 2009). As far as medications 
are concerned, the use of various drugs, such as lithium, 
-blockers, antimalarial agents, nonsteroidal anti-inflam-
matory drugs, and angiotensin-converting enzyme 
inhibitors, has also been associated with induction or 
worsening of disease in psoriatic patients (Abel et al., 
1986; Fry and Baker, 2007). In fact, there may be a 
growing literature of drugs that can aggravate existing 
psoriasis or induce it for the first time.  
In the present time, studies on molecular mechanisms 
underlying psoriasis are not only concerned with 
genetics, but also epigenetics; that is the study of diffe-
rences in phenotype in the absence of variation in the 
genetic code. Epigenetics is associated with the patho-
genesis of various skin diseases including psoriasis 
(Millington, 2008). Such example as hypomethylation has 
been well demonstrated in psoriasis (Ruchusatsawat et 
al., 2006). Still, there may be other trigger factors with 
regard to psoriasis in addition to a genetic and 
immunogenic background, thus supporting psoriasis as a 
multifactorial disease. It is noteworthy that precise 
mechanisms underlying pathophysiology of psoriasis are 
ambiguous. Such mediator as serotonin (5-hydroxytryp-
tamine, 5-HT) should be further investigated with respect 
to psoriasis since serotonin has been revealed to 
essentially connect all three systems closely together 
referred to as neuro-immuno-cutaneous system (Misery, 
1997). In fact, addition of another system has been 
subsequently evident, thus establishing a model known 
as neuro-immuno-cutaneous-endocrine (NICE) (O'Sullivan 
et al., 1998; Locala, 2009). Herein, we review the up-to-
date knowledge about potential role of serotonergic 
genes regarding their expression changes and genetic 
polymorphisms in psoriasis and point out possible 
directions of future studies.  
 
 
ROLE OF SEROTONERGIC GENE EXPRESSION IN 
PSORIASIS 
 
Because psoriasis occurs in connection  with  stress  and  




mood disorders (Peters et al., 2000; Griffiths and Richards, 
2001) and occasionally has been reported to be induced 
in patients after treatment with antidepressants (Barth 
and Baker, 1986; Osborne et al., 2002; Tan Pei Lin and 
Kwek, in press), the pathophysiological role of such 
monoamine as serotonin acting as a neuromediator in the 
central and peripheral nervous systems (Azmitia, 1999; 
Kema et al., 2000), has received considerable attention. 
Serotonin was first isolated about sixty years ago and 
identified to be the vasoconstrictor compound contained 
in serum (Rapport et al., 1948). It was subsequently 
identified as a neurotransmitter synthesized in the central 
nervous system (Jacobs and Azmitia, 1992). Regarding 
serotonin biosynthesis and its related metabolic pathways 
(Figure 1), the first step in the biosynthesis of serotonin is 
catalyzed by tryptophan hydroxylase (TPH), which is the 
rate-limiting enzyme of the pathway. It is encoded by two 
genes: the well characterized tph1 gene (Darmon et al., 
1986) and a subsequently identified tph1 gene. The 
expression of tph1 is non-neuronal while that of tph2 is 
neuronal (Cote et al., 2003; Walther et al., 2003). Degra-
dation of serotonin is controlled by the enzymatic activities 
of monoamine oxidase. In the pineal grand, tryptophan is 
the precursor of melatonin biosynthesis via serotonin. 
The significance of serotonin in neuronal and peripheral 
physiology has been interestingly discussed (Cote et al., 
2004). From that particular review, it is noteworthy that 
the functions of serotonin are closely connected regard-
less of its biosynthetic sources. Serotonin is not only 
produced by enterochromaffin cells of the gut and the 
serotonergic neurons of the brain, but also other cells 
including lymphocytes (O'Connell et al., 2006). It is stored 
in the blood by platelets and released at sites of inflame-
mation (Geba et al., 1996), thus signifying its crucial role 
in chronic inflammatory disorders.  
Stress and stress-related hormones increase serotonin 
synthesis (Azmitia and McEwen, 1969; Azmitia et al., 
1993). Interestingly, circuitry of the stress cascades has 
been thoroughly reviewed by Lechin et al. (2006). In 
particular, serotonergic neurons, which are distributed in 
both dorsal raphe and median raphe, function in res-
ponding to various types of stress, thus leading to an 
increase in cortisol production. Subsequently, cortisol 
released from adrenal grand crosses the blood-brain 
barrier and acts on cortisol receptors located at dorsal 
raphe serotonergic neurons, but not median raphe 
serotonergic ones. For this reason, prolongation of all 
types of stress triggers exhaustion of only dorsal raphe 
serotonergic neurons. The large spectrum of behavioral 
and physiological functions, e.g., in stress and mood, 
influenced by serotonin is mediated via various receptor 
subtypes (Glennon, 2003), and these have been 
classified based on their structural and transductional 
properties (Barnes and Sharp, 1999; Verge and Calas, 
2000).  
The serotonergic system which consists of serotonin 
molecules, serotonin receptors and  serotonin  transporters  
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Figure 1. The schematic presentation of serotonin metabolism in humans. Serotonin is synthesized by a pathway analogous to 
that of the catecholamines. Prior to enzymatic catalysis of tryptophan hydroxylase, the neuronal uptake of tryptophan is 
considerably vital for serotonin biosynthesis in the central nervous system. Metabolism of serotonin is primarily through 
monoamine oxidase yielding the principle metabolite, 5-hydroxy indole acetic acid. In the pineal grand, melatonin is 




(5-HTT) may play a significant role in psoriasis. To sup-
port this hypothesis, our previous study demonstrated 
comparable serotonin levels in serum of psoriatic patients 
and healthy controls, but platelet serotonin concen-
trations were significantly decreased in the patients 
(Tencomnao et al., 2007). Also, immunohistochemical 
techniques showed that expression of serotonin was 
significantly stronger in the prickle cells, sweat gland 
cells, sebaceous gland cells, and hair roots of the lesions 
in the progressive stage of psoriasis than in the static 
stage, while there was no expression of serotonin in the 
specimens of normal skin (Huang et al., 2004). Recently, 
serotonin has been considered one of the mediators of 
pruritus in psoriasis in addition to opioid system, 
prostanoids, interleukin 31 and proteases (Reich and 
Szepietowski, 2007), thus pointing out possible directions 
of future studies aiming the psoriasis pathogenesis. Also, 
as it is known that serotonin is largely stored in platelets, 
platelet functions in such dermal diseases as urticaria, 
atopic eczema/dermatitis sysdrome and psoriasis have 
been reviewed with respect to associations between 
changes in platelet activity and reactivity and pathogenic 
mechanisms (Kasperska-Zajac et al., 2008). For this 
reason, modulation of serotonin levels in psoriasis may 
reflect certain changes in genes encoding enzymes 
crucial for serotonergic metabolism.  
In addition to serotonin, a few genes in the serotonergic 
system have been studied with respect to their expres-
sion in psoriasis. For example, it was demonstrated that 
expression of serotonin 2A receptor (5-HTR2A), a mediator 
of the downstream effects of serotonin, was significantly 





that of normal skin as involved psoriatic skin having the 
highest 5-HTR2A level (Nordlind et al., 2006), thereby 
corroborating its molecular role in promoting cell prolife-
ration (Azmitia, 2001). The 5-HTR2A has been shown to 
be present in activated T cells (Stefulj et al., 2000; Leon-
Ponte et al., 2007). As a result, the 5-HTR2A has received 
much attention since the molecular involvement of 5-
HTR2A in psoriasis has not been fully understood.  
 
 
EFFECT OF GENETIC POLYMORPHISMS IN 
SEROTONERGIC SYSTEM ON PSORIASIS 
 
Regarding the human 5-HTR2A gene, it is located on 
chromosome 13q14-21 (Erdmann et al., 1996), and it 
consists of three exons spanning more than 20 kilobases 
(kb) (Saltzman et al., 1991; Chen et al., 1992). Recently, 
genetic variations in the 5-HTR2A have been discovered 
to associate with rheumatoid arthritis, a chronic and 
systemic autoimmune disorder (Kling et al., 2008), thus 
highlighting the role of SNPs in serotonergic system in 
chronic inflammatory disorders. In deed, two single 
nucleotide polymorphisms (SNPs) of this gene have been 
commonly studied in psychiatric disorders: -1438A/G 
(rs6311) in the promoter region (Collier et al., 1997) and 
102T/C (rs6313) in the exon 1 (Warren et al., 1993). 
Functional studies have recently sought to identify the 
molecular mechanism underlying various genetic studies 
and have focused on both SNPs. Since they are in 
complete linkage disequilibrium (LD) (Ono et al., 2001; 
Ohara et al., 1999), studies investigating one polymor-
phism also provide information about the other. The latter 
SNP does not directly influence the gene expression 
because it does not involve the substitution of an amino 
acid (Bray et al., 2004). In contrast, the former SNP was 
shown to transcriptionally modulate the 5-HTR2A gene 
expression (Parsons et al., 2004; Myers et al., 2007). In 
addition, in silico analysis of -1438A/G allelic variants 
revealed the A allele containing a consensus binding site 
for the transcription factor Th1/E47, and electrophoretic 
mobility shift assay (EMSA) successfully demonstrated 
allele-specific binding to support the bioinformatics 
prediction (Smith et al., 2008). The biological importance 
of this SNP with respect to diseases is also underscored 
based on numerous association studies such as seasonality 
(Lee et al., 2006), tardive dyskinesia (Boke et al., 2007) 
and metabolic syndrome (Halder et al., 2007). The diver-
gences in disease susceptibility may be a reflection of the 
altered density of the receptor crucial for neurotransmitter 
mechanisms, thus making this SNP a promising candidate 
for an association study. Therefore, a case-control design 
should be carried out to investigate the possible involve-
ment of the -1438A/G SNP in psoriasis.  
In addition, this review with regard to psoriasis should 
address another noteworthy component of the serotonergic 
system, 5-HTT. The expression and function of 5-HTT, 
which is responsible for the uptake of 5-HT into cells thus  




removing 5-HT from the extracellular space, is a key 
factor in the regulation of 5-HT-mediated effects in the 
central nervous system and the immune system (Mossner 
and Lesch, 1998). The expression of 5-HTT is regulated 
by a repeat length polymorphism in the 5-HTT linked 
polymorphic region (5-HTTLPR). The long (high activity) 
allele of this polymorphism is associated with a superior 
number of 5-HTT molecules on lymphocytes (Lesch and 
Mossner, 1998). The biological relevance of the 5-
HTTLPR polymorphism is highlighted by several research 
findings including an association with primary pulmonary 
hypertension (Eddahibi et al., 2001), the detected impact 
on the development of depressive symptoms in indivi-
duals afflicted by a negative life event as well as on 
suicidal behavior (Li and He, 2007), the observed 
interaction with attachment security on electrodermal 
reactivity (Gilissen et al., 2008), the noticed effect on the 
symptomatic profile of panic disorder (Lonsdorf et al., 
2009), the risk of sporadic Parkinson's disease (Albani et 
al., 2009) and the endocrine stress response in newborns 
(Mueller et al., 2010). Interestingly, 5-HTT has been 
recently demonstrated to play a role in regulating apoptosis 
in inflammatory cells associated with psoriasis, in which 
case this protein might constitute a valuable therapeutic 
target (Thorslund et al., 2009). Although it has been lately 
reported no association between 5-HTTLPR and 
psoriasis in German Caucasian sample;  in their finding, 
20% of patients with psoriasis suffering from at least mild 
depression, should be noted (Mossner et al., 2009). 
Since 5-HTTLPR allele frequencies have been noticeably 
different with respect to ethnicity, association studies in 
various populations should be conducted in order to gain 





Psoriasis appears to be characterized by stress-induced 
chronic inflammation, and it has been well documented 
that stress and stress-related hormones are associated 
with serotonergic system. In the present work, the author 
addressed the molecular role of serotonergic genes on 
psoriasis. Their molecular impacts, obtained from studies 
on serotonergic gene expression and polymorphism in 
psoriasis, have been increasingly emphasized. In addition 
to the addressed polymorphisms in 5-HTR2A gene and 
5-HTT gene, other functionally relevant genetic variations 
of the serotonergic system may play a part in the etiology 
of psoriasis, and therefore exploring their functional 
significances is highly encouraged. In clinical practice, 
finding or developing drugs influencing the serotonergic 
system might be a simpler mission because these types 
of agents are commercially available for therapeutic pur-
poses. For instance, drugs such as selective serotonin 
reuptake inhibitors are popularly utilized to maintain the 
circulating levels of serotonin. In contrast, medications 
such as tianeptine act by enhancing serotonin uptake by  




platelets and serotonergic axons at the central nervous 
system as previously described (Lechin et al., 2004). The 
bottom line is that the circulating serotonin concentrations 
can be regulated by appropriate therapeutic agents if 
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